Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH

    ... <38.0 kg/m2 Diagnosed with PNH On treatment with eculizumab (Soliris®) for at least 3 months Hb < 10 g/dL at screening ...

    Clinical Trial last updated 08/24/2016 - 11:15am.

  2. Interviews with the Experts: Hemolysis in PNH and Beyond

    ... this process is by blocking the action of complement.  Eculizumab (Soliris®) is an antibody to a component of the complement ... and prevents complement-induced red cells destruction.  Eculizumab has been studied in several clinical trials and is approved by the ...

    Interview last updated 08/31/2016 - 8:40am.

  3. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects with PNH

    ... (PNH) who are still anemic after treatment with eculizumab (Soliris®). ... Diagnosed with PNH On treatment with eculizumab (Soliris®) for at least 3 months Hb < 10 g/dL at ...

    Clinical Trial last updated 07/19/2016 - 12:46pm.

  4. Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study

    ... annual meeting in June focused on the effectiveness of eculizumab (Soliris®). Abstract EHA18ABSSUB-5522 Gerard Socie, ... hemoglobinuria (PNH). Clinical trials have shown that eculizumab (Soliris®) reduces rates of hemolysis , or the destruction ...

    Research Review last updated 05/02/2016 - 9:26am.

  5. Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

    ... Kingdom were the first to treat patients with PNH with eculizumab , and were therefore able to report on long term results. This ... high rate of blood clotting ( thrombosis ) and that eculizumab reduces the chances of this complication by a factor of about 10. ...

    Research Review last updated 05/02/2016 - 9:24am.

  6. Genetic Polymorphism of the Complement Receptor-1 (CR1) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    ... factors that influence how patients will respond to eculizumab . As way of background, some patients with PNH who go on Eculizumab have an increase in their hemoglobin up to the normal range ...

    Research Review last updated 05/02/2016 - 9:25am.

  7. A Rare Genetic Polymorphism in C5 Confers Poor Response to the Anti-C5 Monoclonal Antibody Eculizumab by Nine Japanese Patients with PNH

    ... who seem to have absolutely no benefit at all from eculizumab . Eculizumab binds to and inactivates the C5 complement protein and protects the ...

    Research Review last updated 05/02/2016 - 9:25am.

  8. Improved Fatigue and Quality-of-Life in Patients with Paroxysmal Nocturnal Hemoglobinuria During Treatment with Eculizumab: Data from the Global PNH Registry

    ... PNH have a major impact on patients’ quality of life. Eculizumab (Soliris®) can prevent hemolysis in people with PNH. The ... age 41) in the PNH Registry who had been treated with eculizumab for 12 months. The patients completed questionnaires to assess their ...

    Research Review last updated 05/02/2016 - 9:21am.

  9. Eculizumab

    ... Eculizumab causes the complement system , a part of your immune ...

    Drug last updated 03/24/2016 - 12:32pm.

  10. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients

    ... complement regulators. Blockage of the lytic pathway by eculizumab is the only available therapy for PNH patients and shows ... to untargeted inhibition of all complement pathways by eculizumab. Thus, the molecular design of each C3-opsonin targeted complement ...

    Research Article last updated 04/29/2016 - 12:58pm.